10-QPeriod: Q2 FY2015

DEXCOM INC Quarterly Report for Q2 Ended Jun 30, 2015

Filed August 5, 2015For Securities:DXCM

Summary

DexCom, Inc. (DXCM) reported its financial results for the second quarter and the first half of 2015. The company demonstrated significant revenue growth, with product revenue increasing by approximately 59% year-over-year for the quarter and 58% for the first half. This growth was primarily driven by increased sales volume of their G4 PLATINUM continuous glucose monitoring (CGM) system, particularly disposable sensors. Despite the strong revenue performance, the company continued to operate at a net loss, though the loss narrowed on a per-share basis. Significant investments in research and development, along with increased selling, general, and administrative expenses, contributed to the ongoing net loss. The company maintains a solid liquidity position with approximately $97.5 million in cash, cash equivalents, and marketable securities as of June 30, 2015, and projects sufficient funds to operate through at least June 30, 2016. Management is focused on scaling manufacturing and expanding commercialization efforts, highlighting the growing installed base of customers using their G4 PLATINUM system and the recent launch of the G4 PLATINUM with Share remote monitoring system. Investors should monitor the company's progress in achieving profitability while continuing to expand market share and develop new product iterations.

Financial Statements
Beta
Revenue$92.90M
Cost of Revenue$27.20M
Gross Profit$66.00M
R&D Expenses$24.40M
SG&A Expenses$45.20M
Operating Expenses$69.60M
Operating Income-$3.60M
Interest Expense$100K
Net Income-$3.70M
Shares Outstanding (Basic)318.40M
Shares Outstanding (Diluted)318.40M

Key Highlights

  • 1Product revenue significantly increased by 59% to $92.9 million for the three months ended June 30, 2015, compared to $58.2 million in the prior year period.
  • 2Gross profit grew by 66% to $65.7 million for the quarter, reflecting strong revenue growth and improved gross margins.
  • 3Despite revenue growth, the company reported a net loss of $3.7 million for the quarter, a reduction from $6.0 million in the prior year period.
  • 4Operating expenses, particularly Research & Development and Selling, General & Administrative, saw substantial increases, indicating continued investment in growth and product development.
  • 5Cash, cash equivalents, and marketable securities stood at $97.5 million as of June 30, 2015, providing a healthy liquidity position.
  • 6The company successfully launched the G4 PLATINUM with Share remote monitoring system in Q1 2015, enhancing product offerings.
  • 7Inventory levels increased to $22.4 million from $16.0 million, reflecting preparations for increased sales volume and potential new product launches.

Frequently Asked Questions

DexCom reported strong revenue growth. Product revenue for the three months ended June 30, 2015, increased by 59% to $92.9 million, compared to $58.2 million in the same period of 2014. For the six months ended June 30, 2015, product revenue increased by 58% to $165.7 million from $104.9 million in the prior year.

No, DexCom is not yet profitable. The company reported a net loss of $3.7 million for the three months ended June 30, 2015, and a net loss of $16.6 million for the six months ended June 30, 2015. However, the net loss has narrowed compared to the same periods in the previous year, indicating improvement.

As of June 30, 2015, DexCom had $97.5 million in cash, cash equivalents, and marketable securities. The company believes its current working capital and resources are sufficient to fund operations through at least June 30, 2016.

Operating expenses increased due to significant investments in future growth. Research and Development expenses rose primarily due to additional headcount and costs for developing future products. Selling, General, and Administrative expenses increased to support revenue growth and continued commercialization, driven by higher headcount, selling costs, and marketing expenses. Share-based compensation also contributed to the increase in both categories due to a higher stock price at the grant date.